WuXi Biologics, part of WuXi AppTec, a contract service provider, plans to build an integrated biologics development, clinical, and commercial manufacturing center in Shijiazhuang, Hebei province, North China.

The new biologics center will include process development labs, a clinical manufacturing facility with 5,000-liter bioreactor capacity, and a commercial manufacturing facility with 48,000-liter bioreactor capacity, which will be built to meet cGMP standards of the US, the European Union, and China. The new integrated center will also support the marketing authorization holder system in China. The initial phase of the center will be operational in 2020.

This is the second recent expansion announced by WuXi Biologics. In April 2018, WuXi announced plans to invest EUR 325 million ($392 million) in a new biologics drug-substance manufacturing facility in Mullagharlin, Dundalk, County Louth, Ireland.

Source: WuXi Biologics